Cargando…

CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development

CRLX101 (formerly IT-101) is a first-in-class nanopharmaceutical, currently in Phase 2a development, which has been developed by covalently conjugating camptothecin (CPT) to a linear, cyclodextrin-polyethylene glycol (CD-PEG) co-polymer that self-assembles into nanoparticles. As a nanometer-scale dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Young, Cissy, Schluep, Thomas, Hwang, Jungyeon, Eliasof, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers Ltd 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182091/
https://www.ncbi.nlm.nih.gov/pubmed/22081768
http://dx.doi.org/10.2174/157340711795163866
_version_ 1782212869490737152
author Young, Cissy
Schluep, Thomas
Hwang, Jungyeon
Eliasof, Scott
author_facet Young, Cissy
Schluep, Thomas
Hwang, Jungyeon
Eliasof, Scott
author_sort Young, Cissy
collection PubMed
description CRLX101 (formerly IT-101) is a first-in-class nanopharmaceutical, currently in Phase 2a development, which has been developed by covalently conjugating camptothecin (CPT) to a linear, cyclodextrin-polyethylene glycol (CD-PEG) co-polymer that self-assembles into nanoparticles. As a nanometer-scale drug carrier system, the cyclodextrin polymeric nanoparticle technology, referred to as “CDP”, has unique design features and capabilities. Specifically, CRLX101 preclinical and clinical data confirm that CDP can address not only solubility, formulation, toxicity, and pharmacokinetic challenges associated with administration of CPT, but more importantly, can impart unique biological properties that enhance CPT pharmacodynamics and efficacy.
format Online
Article
Text
id pubmed-3182091
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Bentham Science Publishers Ltd
record_format MEDLINE/PubMed
spelling pubmed-31820912011-11-10 CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development Young, Cissy Schluep, Thomas Hwang, Jungyeon Eliasof, Scott Curr Bioact Compd Article CRLX101 (formerly IT-101) is a first-in-class nanopharmaceutical, currently in Phase 2a development, which has been developed by covalently conjugating camptothecin (CPT) to a linear, cyclodextrin-polyethylene glycol (CD-PEG) co-polymer that self-assembles into nanoparticles. As a nanometer-scale drug carrier system, the cyclodextrin polymeric nanoparticle technology, referred to as “CDP”, has unique design features and capabilities. Specifically, CRLX101 preclinical and clinical data confirm that CDP can address not only solubility, formulation, toxicity, and pharmacokinetic challenges associated with administration of CPT, but more importantly, can impart unique biological properties that enhance CPT pharmacodynamics and efficacy. Bentham Science Publishers Ltd 2011-03 /pmc/articles/PMC3182091/ /pubmed/22081768 http://dx.doi.org/10.2174/157340711795163866 Text en © 2011 Bentham Science Publishers Ltd http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Young, Cissy
Schluep, Thomas
Hwang, Jungyeon
Eliasof, Scott
CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development
title CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development
title_full CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development
title_fullStr CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development
title_full_unstemmed CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development
title_short CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development
title_sort crlx101 (formerly it-101)–a novel nanopharmaceutical of camptothecin in clinical development
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182091/
https://www.ncbi.nlm.nih.gov/pubmed/22081768
http://dx.doi.org/10.2174/157340711795163866
work_keys_str_mv AT youngcissy crlx101formerlyit101anovelnanopharmaceuticalofcamptothecininclinicaldevelopment
AT schluepthomas crlx101formerlyit101anovelnanopharmaceuticalofcamptothecininclinicaldevelopment
AT hwangjungyeon crlx101formerlyit101anovelnanopharmaceuticalofcamptothecininclinicaldevelopment
AT eliasofscott crlx101formerlyit101anovelnanopharmaceuticalofcamptothecininclinicaldevelopment